Noveome Biotherapeutics, Inc. Press Releases - EIN Presswire

Published on March 26, 2026 - 22:28 GMT

Noveome Biotherapeutics Announces Positive Data Safety Monitoring Board Recommendation in ongoing NEC Clinical Trial

Drug Safety Monitoring Board (DSMB) gives Noveome Biotherapeutics a recommendation to continue the Necrotizing Enterocolitis (NEC) study without modifications PITTSBURGH, PA, UNITED STATES, March 26, 2026 /⁨EINPresswire.com⁩/ -- Noveome Biotherapeutics, …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on April 23, 2025 - 13:00 GMT

Noveome Biotherapeutics, Inc. Completes $51 million Series E Financing to Support Clinical Trials in NEC

The financing will be primarily used to support the advancement of the Company’s clinical stage program for the treatment of Necrotizing Enterocolitis PITTSBURGH, PA, UNITED STATES, April 23, 2025 /⁨EINPresswire.com⁩/ -- Noveome Biotherapeutics, Inc. …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on November 20, 2024 - 15:00 GMT

Noveome Biotherapeutics Announces Issuance of U.S. Patent No. 12,121,546 “Treatment of Systemic Inflammatory Responses”

"This patent underscores our ongoing efforts to push the boundaries of innovation" stated Patrick Welch, CEO PITTSBURGH, PA, UNITED STATES, November 20, 2024 /⁨EINPresswire.com⁩/ -- Noveome Biotherapeutics, Inc., is a clinical stage Pittsburgh- …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 14, 2024 - 21:54 GMT

Noveome Biotherapeutics Completes Dosing of First Baby in Clinical Trial for Treatment of Necrotizing Enterocolitis

The NEC Bell Stage 2a-diagnosed baby completed 10 days of treatment, as well as the required 2-week and 1-month post-treatment follow-up visits. PITTSBURGH, PA, UNITED STATES, November 14, 2024 /⁨EINPresswire.com⁩/ -- Noveome Biotherapeutics, Inc., a …

Distribution channels: Business & Economy, Companies ...

Published on December 11, 2023 - 19:04 GMT

Noveome Biotherapeutics, Inc. Receives FDA Notification to Proceed with its Phase 1-2 Clinical Trial in Treatment of NEC

In connection with the FDA notification, Noveome anticipates a closing on at least an additional $13.5 million of Series E convertible preferred stock financing PITTSBURGH, PA, UNITED STATES, December 11, 2023 /⁨EINPresswire.com⁩/ -- Noveome …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on August 17, 2023 - 21:25 GMT

Noveome Biotherapeutics, Inc. Completes First Close of $40 Million Series E Financing to Support Clinical Trials in NEC

The financing will be primarily used to support the advancement of the Company’s clinical stage program, for the treatment of Necrotizing Enterocolitis PITTSBURGH, PA, UNITED STATES, August 17, 2023 /⁨EINPresswire.com⁩/ -- Noveome Biotherapeutics, Inc. …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...